...
首页> 外文期刊>Hepato-gastroenterology. >Prognostic Significance of Initial Recurrence Site in Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma
【24h】

Prognostic Significance of Initial Recurrence Site in Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma

机译:初始复发部位在食管鳞状细胞癌血源性复发中的预后意义

获取原文
获取原文并翻译 | 示例

摘要

Background/Aims: Hematogenous recurrences of esophageal squamous cell carcinoma (ESCC) have dismal prognoses, but prognostic heterogeneity exists in this disease. The objectives of this study were to clarify the prognosis in this disease with regard to the initial recurrence site and to define the prognostic factors. Methodology: We retrospectively reviewed the cases of 67 consecutive patients with hematogenous recurrence in major organs after esophagectomy for ESCC of the thoracic esophagus and the esophagogastric junction. We analyzed clinicopathological characteristics, survival probability and potential prognostic factors. Results: Lung, liver, bone, and multiple-organ metastases occurred in 24, 19, 14, and 10 patients, respectively. Twenty-seven patients simultaneously had locoregional recurrence (combined recurrence). Among all 67 patients, the median disease-free interval (DFI) was 9.7 months, and the median survival time after the initial recurrence was 4.9 months. The patients with initial lung metastasis had most favorable prognosis with the median survival time of 9.8 months. A multivariate analysis identified that initial recurrence site, DFI, combined recurrence, and anticancer therapy were independent prognostic factors. Conclusions: The initial recurrence site contributes to the prognostic heterogeneity of patients with hematogenous recurrence of ESCC. The prognostic factors identified in this study are useful to optimize the management of these patients.
机译:背景/目的:食管鳞状细胞癌(ESCC)的血源性复发预后不良,但该病存在预后异质性。这项研究的目的是就初始复发部位明确该病的预后并确定预后因素。方法:我们回顾性分析了因食管和食管胃交界处食管切除术而在食管切除术后连续发生的67例主要器官血肿复发的病例。我们分析了临床病理特征,生存概率和潜在的预后因素。结果:分别有24、19、14和10例患者发生了肺,肝,骨和多器官转移。 27例患者同时发生局部复发(合并复发)。在全部67例患者中,无病间隔(DFI)的中位数为9.7个月,初次复发后的中位生存时间为4.9个月。最初有肺转移的患者预后最理想,中位生存时间为9.8个月。多因素分析表明,初始复发部位,DFI,联合复发和抗癌治疗是独立的预后因素。结论:最初的复发部位有助于ESCC血源性复发患者的预后异质性。本研究中确定的预后因素有助于优化这些患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号